- Business Wire•2 days ago
Swedish Orphan Biovitrum AB today announces that the company’s product Alprolix® , a recombinant human factor IX Fc-fusion protein with extended half-life for the treatment of haemophilia B, has now been approved for reimbursement across the UK.
- Business Wire•5 days agoSwedish Orphan Biovitrum AB: Elocta® Obtains National Reimbursement in Spain, Now Available in the Five Largest Markets in the EU
Swedish Orphan Biovitrum AB today announces that the company’s product Elocta® , a recombinant human factor VIII Fc-fusion protein with an extended half-life for the treatment of haemophilia A, has received national reimbursement approval in Spain.
Swedish Orphan Biovitrum AB (SOBI.ST)
Stockholm - Stockholm Delayed Price. Currency in SEK
|Day's Range||105.00 - 106.70|
|52wk Range||92.60 - 140.30|
|1y Target Est||N/A|
|P/E Ratio (ttm)||50.26|
|Avg Vol (3m)||950,862|
|Dividend & Yield||N/A (N/A)|